Dottikon ES Holding AG(0ACK)
GBP --+0.00%
Reward60Moderate
Risk53Moderate
📊25%Data
Strong 28% profit margin · Revenue growing 25% YoY
0ACK
+0.0 · +0.00%
GBP · LSE
Dottikon ES Holding AG |
Balanced
Market Cap:
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
25% data coverage
ℹ️
Risk Rating
53
Moderate
Risk Assessment
50% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0ACK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Dottikon ES Holding AG?

Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia.

0ACK · Verdict

Solid reward · elevated risk

0ACK leads on growth with the rest of the factors in line with peers.

Based on 38% data coverage

0ACK · Verdict

What’s working & what to watch

Strengths 1

  • Growth70/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Dottikon ES Holding AG?

Dottikon ES Holding AG manufactures and sells performance chemicals, intermediates, and active pharmaceutical ingredients for the chemical, biotech, and pharmaceutical maceutic industries in Europe, Switzerland, the United States, and Asia. The company's chemicals and intermediates include amines, anilines, azaindoles, benzimidazoles, benzoic acid derivatives, benzyl compounds, boron building blocks, chiral compounds, cyclohexane derivatives, cyclopropyl building blocks, indazoles, indoles, N-heterocycles, nitrate esters, nitroaromatic compounds, O-heterocycles, phenols and anisoles, and pyridine building blocks. The company is listed on the LSE in UK.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market CapN/A
P/E RatioN/A
Dividend YieldN/A
52 Week High384.5
52 Week Low195.2
Last AnnualMarch
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees875
IndustryN/A
ExchangeLSE
Beta1.002
CurrencyGBP